4.7 Review

Mitochondrion-targeted RNA therapies as a potential treatment strategy for mitochondrial diseases

Journal

MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 30, Issue -, Pages 359-377

Publisher

CELL PRESS
DOI: 10.1016/j.omtn.2022.10.012

Keywords

-

Funding

  1. Canadian Institutes of Health Research (CIHR) [ACA 505546]
  2. Canada Research Chair (CIHR) [501090]
  3. Department of Pharmacology, University of Toronto

Ask authors/readers for more resources

This article investigates the current treatment options for mitochondrial diseases and explores the potential of RNA-based therapeutic strategies, including the use of ASOs and RNAi drugs, allotopic therapies, and RNA-based antigenomic therapies. Furthermore, various mechanisms for delivering RNA therapeutic agents to the mitochondrial matrix are reviewed.
Mitochondrial diseases are one of the largest groups of neurological genetic disorders. Despite continuous efforts of the scientific community, no cure has been developed, and most treatment strategies rely on managing the symptoms. After the success of coronavirus disease 2019 (COVID-19) mRNA vaccines and accelerated US Food and Drug Administration (FDA) approval of four new RNAi drugs, we sought to investigate the potential of mitochondrion-targeting RNA-based therapeutic agents for treatment of mitochondrial diseases. Here we describe the causes and existing therapies for mitochondrial diseases. We then detail potential RNA-based therapeutic strategies for treatment of mitochondrial diseases, including use of antisense oligonucleotides (ASOs) and RNAi drugs, allotopic therapies, and RNA-based antigenomic therapies that aim to decrease the level of deleterious heteroplasmy in affected tissues. Finally, we review different mechanisms by which RNA-based therapeutic agents can be delivered to the mitochondrial matrix, including mitochondrion-targeted nanocarriers and endogenous mitochondrial RNA import pathways.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available